Abstract: Systems and methods provide real-time shipping optimization recommendations for reducing the cost of shipping freight units in a shipment. System comprises a measurement system in communication with a computer system that comprises a client computer device in communication with a host computer system. The measurement system comprises multiple sensing devices to determine weight, dimensions, and other shipping parameters of the freight units in the shipment. The computer system computes a current shipping cost and density based on the shipping parameters. The computer system determines shipping recommendations including recommended adjustments to the shipping parameters that reduce the current shipping cost. The shipping recommendations are transmitted to the client computer device prior to loading the shipment onto a carrier vehicle for the shipment.

Abstract: A method includes: receiving, at a clinical intelligent agent, patient specific data comprising information regarding the condition of the patient in a room; determining an event requiring action has occurred with respect to the patient, wherein the determining comprises comparing, using a monitor of the clinical intelligent agent, the patient specific data with historical reference data; displaying one or more alerts on a patient screen; scoring, using the clinical intelligent agent, the one or more alerts, wherein the scoring comprises escalating the one or more alerts based upon a response to the one or more alerts; and prioritizing, using the clinical intelligent agent, care provider tasks displayed on the patient screen based on the score of the one or more alerts. Other aspects are described and claimed.

Abstract: Systems and methods provide real-time shipping optimization recommendations for reducing the cost of shipping freight units in a shipment. System comprises a measurement system in communication with a computer system that comprises a client computer device in communication with a host computer system. The measurement system comprises multiple sensing devices to determine weight, dimensions, and other shipping parameters of the freight units in the shipment. The computer system computes a current shipping cost and density based on the shipping parameters. The computer system determines shipping recommendations including recommended adjustments to the shipping parameters that reduce the current shipping cost. The shipping recommendations are transmitted to the client computer device prior to loading the shipment onto a carrier vehicle for the shipment.

Abstract: Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.

Abstract: Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.

Abstract: A method includes: receiving, at a clinical intelligent agent, patient specific data comprising a room location of a patient within a healthcare facility and information regarding the condition of the patient in the room; comparing, using a monitor of the clinical intelligent agent, patient specific data with historical reference data to detect clinical patterns; producing, using an alerting agent of the clinical intelligent agent, one or more alerts when a processor identifies a clinical pattern indicating an alert situation; sending, using the alerting agent, the one or more alerts to a patient screen located in the room occupied by the patient; scoring, using the clinical intelligent agent, the one or more alerts; and prioritizing, using the clinical intelligent agent, care provider tasks displayed on the patient screen based on the score of the one or more alerts. Other aspects are described and claimed.

Abstract: Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.

Abstract: Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.

Abstract: A method includes: receiving patient specific data; comparing the patient specific data with reference data; producing alerts when the comparison determines that an event requiring action has occurred; and sending the alerts to care providers. An apparatus that implements the method and a computer readable medium including instructions for performing the method are also provided.

Abstract: Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.

Abstract: Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.

Abstract: Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.

Abstract: Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.

Abstract: Disclosed herein are processes for making L-ornithine phenyl acetate. The process may include, for example, intermixing a halide salt of L-ornithine with silver phenyl acetate. The process may also include forming a phenyl acetate salt in situ. The present application also relates to various compositions obtained from these processes, including crystalline forms.

Abstract: Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.

Abstract: Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.

Abstract: Disclosed herein are processes for making L-ornithine phenyl acetate. The process may include, for example, intermixing a halide salt of L-ornithine with silver phenyl acetate. The process may also include forming a phenyl acetate salt in situ. The present application also relates to various compositions obtained from these processes, including crystalline forms.

Abstract: Disclosed herein are processes for making L-ornithine phenyl acetate. The process may include, for example, inter-mixing a halide salt of L-ornithine with silver phenyl acetate. The process may also include forming a phenyl acetate salt in situ. The present application also relates to various compositions obtained from these processes, including crystalline forms.

Abstract: Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.

Abstract: Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.